Goodwin advised Nimbus Therapeutics on the financing. Nimbus Therapeutics announced its $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The...
You must be a Standard 1 Year member to access this content.
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
You must be a Standard 1 Year member to access this content.
Goodwin advised Akero Therapeutics on the offering, and Cooley advised the underwriter involved. Akero Therapeutics (Nasdaq: AKRO) announced the closing of its underwritten registered direct offering...
You must be a Standard 1 Year member to access this content.
Goodwin advised ElevateBio on the financing. ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised MOMA Therapeutics on the deal. MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 7,187,500 shares of its common stock, including...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised ElevateBio on the deal. ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced it...
You must be a Standard 1 Year member to access this content.
